Skip to main content
. 2021 Apr 26;13(9):2090. doi: 10.3390/cancers13092090

Figure 5.

Figure 5

Optical coherence tomography (OCT) scans of a male patient with metastatic melanoma started targeted therapy with encorafenib and binimetinib. Two days after therapy initiation, he noticed blurry vision. On OCT, serous retinal detachment with subfoveolar fluid (a, arrowhead) is observed, which spontaneously resolved after withholding targeted therapy for 5 days (b).